D. Wexler

Effect of Quinolone Antimicrobials on Theophylline Pharmacokinetics

J. Lettieri, E. Casabar, C. Adair, 1989, Journal of clinical pharmacology.

Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults.

E. Radwanski, R. Courtney, Josephine Lim, 2003, British journal of clinical pharmacology.

Pharmacokinetics, Safety, and Efficacy of Posaconazole in Patients with Persistent Febrile Neutropenia or Refractory Invasive Fungal Infection

D. Kontoyiannis, R. Courtney, I. Raad, 2006, Antimicrobial Agents and Chemotherapy.

A Brief Survey of First‐in‐Human Studies

K. Bertelsen, D. Wexler, 2011, Journal of clinical pharmacology.

Pharmacokinetics, Safety, and Efficacy of Posaconazole in Patients with Persistent Febrile Neutropenia or Refractory Invasive Fungal Infection

D. Kontoyiannis, R. Courtney, I. Raad, 2006 .

Oral Bioavailability of Posaconazole in Fasted Healthy Subjects

R. Courtney, F. Ezzet, G. Krishna, 2005, Clinical pharmacokinetics.

Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study.

C. Banfield, R. Courtney, Josephine Lim, 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Effect of a Nutritional Supplement on Posaconazole Pharmacokinetics following Oral Administration to Healthy Volunteers

G. Krishna, B. Kantesaria, Mitchell Rosenberg, 2006, Antimicrobial Agents and Chemotherapy.

A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe.

T. Kosoglou, P. Statkevich, V. Batra, 2001, Clinical therapeutics.

Canagliflozin, a novel inhibitor of sodium glucose co‐transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

D. Wexler, P. Rothenberg, D. Devineni, 2011, Diabetes, obesity & metabolism.

P779 Pharmacokinetics of ceftobiprole following single and multiple intravenous infusions administered to healthy subjects

G. Noel, D. Skee, D. Balis, 2007 .

Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.

William Smith, E. Wajs, T. Marbury, 2015, Clinical therapeutics.